Genetic Modifiers of Cardiac Remodeling Severity in IVS4+919G>A-Associated Fabry Cardiomyopathy
International Journal of Molecular Sciences · 20.08.2026 · 27 (16) · 7447
DOI: 10.3390/ijms27167447 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.08.2026. Verfasst von Kuo-Tzu Sung und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan. Hauptthemen laut MEDLINE: Fabry Disease, alpha-Galactosidase, Hypertrophy, Left Ventricular, Ventricular Remodeling. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi Genzyme.
Abstract (Originalsprache)
The GLA IVS4+919G>A founder variant causes a late-onset, cardiac-predominant form of Fabry disease, yet the severity of cardiac remodeling varies markedly among affected men. We studied 167 unrelated male carriers. Genome-wide association analyses included 81 men aged ≥50 years for left ventricular hypertrophy (LVH; left ventricular mass index [LVMI] ≥ 51 g/m2.7) and septal hypertrophy (interventricular septal thickness at end-diastole [IVSd] ≥ 1.2 cm), and 149 men with plasma globotriaosylsphingosine (lyso-Gb3) measurements. Genotyping was performed with the Axiom Genome-Wide TPM 2.0 Array. Mean LVMI increased from 34.6 ± 11.3 g/m2.7 at 20–39 years to 75.1 ± 34.0 g/m2.7 at ≥60 years, although substantial variability persisted within each age stratum. rs1435166 and rs2572260, located in the adjacent EGLN1/SPRTN region, showed identical associations with LVH (both p = 4.14 × 10−8) and concordant genotypes in all 81 participants (dosage r2 = 1.00; D′ = 1.00), indicating a single regional association signal. The association remained evident in exact testing, Firth logistic regression, and an age-adjusted continuous-LVMI analysis yielded concordant results. In the age-adjusted analysis, each rs1435166 T allele was associated with a 12.8 g/m2.7 lower LVMI. Two intergenic variants met the exploratory threshold for septal hypertrophy, whereas no variant reached genome-wide significance for lyso-Gb3. These findings support the hypothesis that inherited genetic background contributes to variation in cardiac remodeling severity among carriers of the same pathogenic GLA variant. Independent replication, regional fine-mapping, and functional validation are required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.
- Division of Cardiology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei 104217, Taiwan.
- Department of Medicine, MacKay Medical University, New Taipei City 252005, Taiwan.
- Department of Pediatrics, Taipei Veterans General Hospital, Taipei 112201, Taiwan.
- Institute of Biomedical Sciences, MacKay Medical University, New Taipei City 252005, Taiwan.
- Institute of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli 350401, Taiwan.
ORCID-Profile: Kuo-Tzu Sung
Förderung
- Sanofi Genzyme
Zitieren
APA
Sung, K. T., Hsu, C. Y., Lu, Y. H., Hung, C. L., & Niu, D. M. (2026). Genetic Modifiers of Cardiac Remodeling Severity in IVS4+919G>A-Associated Fabry Cardiomyopathy. International Journal of Molecular Sciences, 27(16), 7447. https://doi.org/10.3390/ijms27167447
Vancouver
Sung KT, Hsu CY, Lu YH, Hung CL, Niu DM. Genetic Modifiers of Cardiac Remodeling Severity in IVS4+919G>A-Associated Fabry Cardiomyopathy. International Journal of Molecular Sciences. 2026;27(16):7447. doi:10.3390/ijms27167447
BibTeX
@article{Sung2026,
author = {Sung, Kuo-Tzu and Hsu, Chih-Yen and Lu, Yung-Hsiu and Hung, Chung-Lieh and Niu, Dau-Ming},
title = {Genetic Modifiers of Cardiac Remodeling Severity in IVS4+919G>A-Associated Fabry Cardiomyopathy},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {16},
pages = {7447},
doi = {10.3390/ijms27167447}
}
EUVIMED